Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 101 results for anticoagulation

  1. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  2. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  3. Balloon cryoablation for Barrett's oesophagus (HTG767)

    Evidence-based recommendations on balloon cryoablation for Barrett's oesophagus. This involves freezing and destroying the abnormal cells using a balloon inflated with very cold gas.

  4. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1122)

    Evidence-based recommendations on amivantamab (Rybrevant) with lazertinib (Lazcluze) for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.

  5. Chronic heart failure in adults: diagnosis and management (NG106)

    This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.

  6. Pulsed-field ablation for atrial fibrillation (HTG755)

    Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.

  7. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  8. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  9. Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension (HTG741)

    Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal nerves.

  10. Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)

    NICE is unable to make a recommendation about the use in the NHS of andexanet alfa (Ondexxya) for reversing anticoagulation in adults with intracranial haemorrhage. This is because AstraZeneca did not provide an evidence submission.

    Sections for TA1029

  11. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  12. Caval valve implantation for tricuspid regurgitation (HTG726)

    Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.

  13. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  14. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  15. NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation

    NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).